ORM NAMCS-CCS

Only ONE.)

1 General/Family 2 Internal 3 OB/ 4 CHC Mid-level Medicine

GYN

U.S. DEPARTMENT OF COMMERCE Economics and Statistics Administration
U.S. CENSUS BUREAU
ACTING AS DATA COLLECTION AGENT FOR THE U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics

NATIONAL AMBULATORY MEDICAL CARE SURVEY 2009 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS E-11, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality - All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used for statistical purposes only by NCHS staff, contractors, and agents only when required and with necessary controls, and will not be disclosed or released to other persons without the consent of the individual or establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m) and the Confidential Information Protection and Statistical Efficiency Act (PL-107-347).

Provider

BACKGROUND INFORMATION

0015 B. Census contact name

©. Provider's serial number	C	ensus ontact elephor	Area code Number						
The Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in community health centers and private office settings. Please answer the following questions. We appreciate your time on this important public health concern.									
	_		Mark (X	() one inte	erval for r	outine so	reening.		
 Does your practice use any of the following methods to screed cervical cancer? Mark (X) all that apply. Conventional Pap test (Definition – Smear spread on glass slitter) 	de and fixed))	 Annually	Every 2 years	Every 3 years	More than 3 years	No routine interval recom- mended		
1 Yes – How often does your practice routinely screen wor using this method? 2 No 3 Unknown Continue with item 1b	nen		1 1 1 1	2	3 🗆	4	5		
b. Liquid-based cytology (Definition – Specimen suspended in liconom 1 Yes – How often does your practice routinely screen women using this method? 2 No 3 Unknown Continue with item 1c	 	2	3	4 🗆	5				
c. Other – Specify ∠			1						
5005 1 Yes - How often does your practice routinely screen wor this method? 2 No 3 Unknown	men using		 - - - - -	2	з□	4□	5 🗆		
2. Does your practice perform colposcopy? 1 Yes 2 No 3 Unknown			1		l		ı		

0070	Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test? 1 Yes - Go to item 3b 2 No - SKIP to item 3c 3 Not aware of HPV DNA test 4 Unknown Which of the following HPV DNA tests are ordered or	4a.	If a patient's Pap test result is borderline or abnormal, does your practice routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the Pap test or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.) 1 Yes – Go to item 4b
0075	collected in your practice? <i>Mark (X) all that apply.</i> 1 High risk (HR) HPV DNA test		2 ☐ No 3 ☐ Unknown } SKIP to item 5a
	2 Low risk (LR) HPV DNA test 3 Not aware there was a high risk or low risk HPV DNA test 4 Type-specific HPV DNA test 5 Unknown	b.	For which borderline or abnormal Pap test result would your practice order or collect a reflex HPV DNA test? Mark (X) all that apply. 1 ASC-US (atypical squamous cells of undetermined significance)
c.	Why is the HPV DNA test not ordered or collected in your practice? – Mark (X) all that apply.		2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion)
0080	My practice does not see the types of patients for whom the HPV DNA test is indicated.		3 LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1)
	2 My practice uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA test is indicated.		4 ☐ HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) 5 ☐ AGC (atypical glandular cells)
	₃ ☐ The patients in my practice have timely access to colposcopy.	c.	For which patients does your practice usually order reflex
	4 Assessing patients' HPV infection status is not a priority at my practice.	0095	HPV DNA testing? – <i>Mark (X) all that apply.</i> 1 □ Women under 21 years old
	5 The labs affiliated with my practice do not offer the HPV DNA test.		2 Women 21 years old to 29 years old 3 Women 30 years old and over
	6 ☐ The health plans or health systems affiliated with my practice do not recommend the HPV DNA test.		4□ Other – Specify
	7 ☐ The HPV DNA test is not a reimbursed or covered service for most patients in my practice.	5010	
	8 ☐ Discussing cervical cancer screening in the context of an STD is avoided in my practice.	5a.	Does your practice routinely recall patients to come back for a second sample collection for an HPV DNA test if their Pap test is abnormal or borderline (recall testing)?
	9 Notifying or counseling patients about positive HPV DNA test results would take too much time.	0100	1 Yes – Go to item 5b
	Notifying or counseling patients about positive HPV DNA test results might make clinicians in my practice feel uncomfortable.		SKIP to item 6a on page 3
	11 ☐ Notifying or counseling patients about positive HPV DNA test results might make patients in my practice feel uncomfortable, angry, or upset.		For which abnormal or borderline Pap test result would your practice recall a patient for an HPV DNA test? Mark (X) all that apply. 1 ASC-US (atypical squamous cells of
	SKIP to item 7 on page 3.		undetermined significance) 2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion)
			3 ☐ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1)
			4 HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ)
			5 ☐ AGC (atypical glandular cells)

Page 2 FORM NAMCS-CCS (11-21-2008)

6a.	Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
0110	1 ☐ Yes – Go to item 6b 2 ☐ No										
	3 ☐ Unknown } SKIP to item 7										
b.	For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? <i>Mark (X) all that apply.</i>										
0115	15 1 ☐ Women under 21 years old 2 ☐ Women 21 years old to 29 years old										
	3 ☐ Women 30 years old and over										
	 4 ☐ Women who request the test for cervical cancer screening 5 ☐ Women who request the test to check their HPV infection status 										
	6 ☐ Other – Specify										
5015	5015										
7.	Giv	en the following scre	ening histo	ories, whe	n would you	ur practice r	ecommend tl	nat a woma	ın between	30 and	
	60 years of age return for her next Pap test? For each of the following scenarios, mark (X) only ONE for each row.										
		ap test results	Current	Current	No			anos, man	K (X) Offig		Have no experience
	(exclı	uding current mal results)		Pap test result	follow-up needed	Less than 6 months	6 months to less than 1 year	1 year	2 years	3 years or more	with this type of patient or test
0120	(a)	Two consecutive normal Pap tests	Has not had test	Normal	1	2	3 🗌	4	5	6 🗆	7 🗌
0125	(b)	Two consecutive normal Pap tests	 Negative	Normal	1	2	3 🗌	4	5	6	7
0130	(c)	Two consecutive normal Pap tests	 Positive	Normal	1	2	3 🗆	4	5 🗌	6	7 🗌
0135	(d)	Has not had a Pap test	 Negative	Normal	1	2	3 🗌	4	5 🗌	6	7 🗌
0140	(e)	Has not had a Pap test	Positive	Normal	1	2	3 🗌	4	5	6	7
0145	(f)	Abnormal Pap test	Negative	Normal	1 🗆	2	3 🗆	4	5 🗌	6	7 🗌
0150	(g)	Abnormal Pap test	Positive	Normal	1	2	3 🗆	4	5	6	7
	QUESTIONS 8-14 ASK ABOUT THE HPV VACCINE										
8.	8. How often does your practice use an HPV test to determine who should get the HPV vaccine? Mark (X) only one.										
	1 ☐ Rarely or never 2 ☐ Sometimes										
	3 ☐ Usually										
		Always or almost a		accino - S	KIP to itom	10					
5 ☐ Do not recommend the HPV vaccine <i>-SKIP to item 10.</i>											

FORM NAMCS-CCS (11-21-2008) Page 3

9.	As it relates to the HPV vaccine,								
	how often does your practice –	Rarely or never		Sometimes	Usually	Always or almost always	Unknown/Not applicable/		
0120	Mark (X) only ONE for each row.	110101				amayo	Do not ask		
0120	a. Use the number of sexual partners to determine who should get the HPV vaccine?	1 🗆		2	з 🗆	4 🗌	5 🗌		
0125	b. Perform a Pap test to determine who should get the HPV vaccine?	1 🗆		2	3 🗆	4 🗆	5 🗆		
0130	c. Recommend the HPV vaccine to females with a history of an abnormal Pap test result (ASC-US or higher)?	1 🗆		2	3□	4	5 🗆		
0135	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗆		2	3 🗌	4 🗆	5		
10.	Mill your practice's cervical cancer screening and management procedures change for females who have been fully vaccinated with the HPV vaccine? □ Yes □ No − SKIP to item 14								
11.	How will your practice determine when to state cervical cancer screening for fully HPV vacce females? Mark (X) all that apply.		age as non-HPV ed females – age	→					
	man (v) all that apply.		 	2□ At a later					
				Specify a	•	→			
			2	≥ By onset of s How many ye	ear(s) since				
			 	onset of sexu	•	/	ala a		
			1	I Unknown	reening fully HP	/ vaccinated fema	ales		
12.	How often will your practice routinely screen for cervical cancer among females that have been fully vaccinated with the HPV vaccine? Mark (X) one. 1 Annually 2 Every 2–3 years 3 Every 4–5 years 4 Greater than every 5 years 5 Will not be screening fully HPV vaccinated females 6 Unknown								
13.	Will your practice be using the HPV DNA test for managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine? 1								
14.	Please indicate to what extent you agree, di with each statement. Please respond to both	Agree	Disagree	Unsure					
	There will be fewer numbers of abnormal Pap tests among vaccinated females.				1 🗆	2	3 🗌		
	b. There will be fewer referrals for colpose vaccinated females.					2	3 🔲		
	5. The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this practice currently participating in this state or national screening program?								
0155	1 Yes 2 No 3 Unknown 6. For purposes of this survey, which of the following categories describe your profession? − Mark (X) only ONE.								
		niowing catego							
0160	1 □ Physician 2 □ Physician assistant/ 3 □ Registered nurse 4 □ Other office staff Nurse practitioner/ Nurse midwife								

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NAMCS-CCS (11-21-2008)